Source link : https://newshealth.biz/health-news/moving-car-t-into-earlier-lines-of-myeloma-treatment/

(MedPage Today) — Updated results from the CARTITUDE-1 trial showed that 33% of patients with heavily pretreated relapsed/refractory multiple myeloma who received ciltacabtagene autoleucel (cilta-cel; Carvykti) were alive and progression free… Source link : https://www.medpagetoday.com/spotlight/asco-mm/116211 Author : Publish date : 2025-06-24 13:40:00 Copyright for syndicated content belongs to the linked Source.

The post Moving CAR-T Into Earlier Lines of Myeloma Treatment first appeared on News Health.

—-

Author : News Health

Publish date : 2025-06-24 13:40:00

Copyright for syndicated content belongs to the linked Source.

—-

12345678